In the context of GBM, MGMT promoter methylation is typically associated with a better response to alkylating chemotherapy, as the reduced expression of MGMT allows these drugs to induce more effective DNA damage in tumor cells, leading to cell death. This evidence concerns the gene MGMT and glioblastoma.